+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Systemic Lupus Erythematosus (Sle) Drugs - Global Market Trajectory & Analytics

  • ID: 5140542
  • Report
  • September 2020
  • Region: Global
  • 105 pages
  • Global Industry Analysts, Inc
Global Systemic Lupus Erythematosus (Sle) Drugs Market to Reach US$264.5 Million by the Year 2027

Amid the COVID-19 crisis, the global market for Systemic Lupus Erythematosus (Sle) Drugs estimated at US$183.3 Million in the year 2020, is projected to reach a revised size of US$264.5 Million by 2027, growing at a CAGR of 5.4% over the period 2020-2027.

The U. S. Accounts for Over 29.5% of Global Market Size in 2020, While China is Forecast to Grow at a 5% CAGR for the Period of 2020-2027

The Systemic Lupus Erythematosus (Sle) Drugs market in the U. S. is estimated at US$54 Million in the year 2020. The country currently accounts for a 29.48% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$46.6 Million in the year 2027 trailing a CAGR of 5% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.1% and 4.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR while Rest of European market (as defined in the study) will reach US$46.6 Million by the year 2027. We bring years of research experience to this 8th edition of our report. The 105-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others:
  • Amgen, Inc.
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline PLC
  • Immunomedics, Inc.
  • Johnson & Johnson
  • MedImmune LLC
  • Merck Serono GmbH
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
Note: Product cover images may vary from those shown
I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
  • Impact of Covid-19 and a Looming Global Recession
  • Global Competitor Market Shares
  • Systemic Lupus Erythematosus (Sle) Drugs Competitor Market Share Scenario Worldwide (in %): 2018E
2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Current & Future Analysis for Systemic Lupus Erythematosus (Sle) Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027
  • TABLE 2: World Historic Review for Systemic Lupus Erythematosus (Sle) Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017
  • TABLE 3: World 15-Year Perspective for Systemic Lupus Erythematosus (Sle) Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2018 & 2027
III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES
  • TABLE 4: USA Current & Future Analysis for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027
  • TABLE 5: USA Historic Review for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017
CANADA
  • TABLE 6: Canada Current & Future Analysis for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027
  • TABLE 7: Canada Historic Review for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017
JAPAN
  • TABLE 8: Japan Current & Future Analysis for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027
  • TABLE 9: Japan Historic Review for Systemic Lupus Erythematosus (Sle) Drugsby Segment - Systemic Lupus Erythematosus (Sle) Drugs Markets - Independent Analysisof Annual Sales in US$ Million for Years 2012 through 2017
CHINA
  • TABLE 10: China Current & Future Analysis for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027
  • TABLE 11: China Historic Review for Systemic Lupus Erythematosus (Sle) Drugsby Segment - Systemic Lupus Erythematosus (Sle) Drugs Markets - Independent Analysisof Annual Sales in US$ Million for Years 2012 through 2017
EUROPE
  • TABLE 12: Europe Current & Future Analysis for Systemic Lupus Erythematosus(Sle) Drugs by Geographic Region - France, Germany, Italy, UK and Rest of EuropeMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2018 through 2027
  • TABLE 13: Europe Historic Review for Systemic Lupus Erythematosus (Sle) Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017
  • TABLE 14: Europe 15-Year Perspective for Systemic Lupus Erythematosus (Sle) Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2018 & 2027
FRANCE
  • TABLE 15: France Current & Future Analysis for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027
  • TABLE 16: France Historic Review for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017
GERMANY
  • TABLE 17: Germany Current & Future Analysis for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027
  • TABLE 18: Germany Historic Review for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017
ITALY
  • TABLE 19: Italy Current & Future Analysis for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027
  • TABLE 20: Italy Historic Review for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017
UNITED KINGDOM
  • TABLE 21: UK Current & Future Analysis for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027
  • TABLE 22: UK Historic Review for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017
REST OF EUROPE
  • TABLE 23: Rest of Europe Current & Future Analysis for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027
  • TABLE 24: Rest of Europe Historic Review for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017
ASIA-PACIFIC
  • TABLE 25: Asia-Pacific Current & Future Analysis for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027
  • TABLE 26: Asia-Pacific Historic Review for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017
REST OF WORLD
  • TABLE 27: Rest of World Current & Future Analysis for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027
  • TABLE 28: Rest of World Historic Review for Systemic Lupus Erythematosus (Sle) Drugs by Segment - Systemic Lupus Erythematosus (Sle) Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017
IV. COMPETITION
  • Total Companies Profiled: 41
Note: Product cover images may vary from those shown
Adroll
adroll